Scientists hunt for immune cells that could lead to new MPN therapies
NCT ID NCT07590986
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the immune system reacts to myeloproliferative neoplasms (MPN), a group of blood cancers. Researchers will collect blood and bone marrow samples from 150 adults with or without MPN to find special immune cells (T cells) that recognize and attack MPN cells. The goal is to identify targets and receptors that could be used to design future immune-based treatments. Participants will not receive direct medical benefit, but their samples will help advance MPN research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESSENTIAL THROMBOCYTHEMIA (ET) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
de Duve Institute, UCLouvain
RECRUITINGBrussels, Woluwe, 1200, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted drug outperform standard care for rare blood cancers?
- Can a Dual-Action pill tame bone marrow tumors?
- Can a new pill tame myelofibrosis?
- New pill shows promise for rare blood cancers in early trial
- New transplant cocktail aims to tame blood cancer without severe side effects
- Momelotinib access expanded for myelofibrosis patients in Long-Term safety study